Abstract:Abstract Aims Hereditary transthyretin amyloidosis (ATTRv) is one of the leading aetiologies of systemic amyloidosis with more than 135 mutations described and a broad spectrum of clinical manifestations. We aimed to provide a systematic description of a population of individuals carrying pathogenic mutations of transthyretin (TTR) gene and to investigate the major clinical events during follow-up. Methods and results This was an observational, retrospective, cohort study including consecutive patients with mutations of TTR gene, admitted to a tertiary referral centre in Bologna, Italy, between 1984 and 2022. Three hundred twenty-five patients were included: 106 asymptomatic carriers, 49 cardiac phenotype, 49 neurological phenotype, and 121 mixed phenotype. Twenty-two different mutations were found, with Ile68Leu (41.8%), Val30Met (19%), and Glu89Gln (10%) being the most common. After a median follow-up of 51 months, 111 patients (38.3%) died and 9 (11.5%) of the 78 asymptomatic carriers developed ATTRv. Carriers had a prognosis comparable with healthy population, while no significant differences were seen among the three phenotypes adjusted by age. Age at diagnosis, New York Heart Association class III, left ventricular ejection fraction, modified polyneuropathy disability score IV, and disease-modifying therapy were independently associated with survival. Conclusion This study offers a wide and comprehensive overview of ATTRv from the point of view of a tertiary referral centre in Italy. Three main phenotypes can be identified (cardiac, neurological, and mixed) with specific clinical and instrumental features. Family screening programmes are essential to identify paucisymptomatic affected patients or unaffected carriers of the mutation, to be followed through the years. Lastly, disease-modifying therapy represents an evolving cornerstone of the management of ATTRv, with a great impact on mortality.

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

Treatment of cardiac transthyretin amyloidosis: an update

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

Hereditary Transthyretin Amyloidosis Polyneuropathy

Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability

Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Therapy of ATTR Cardiac Amyloidosis: Current Indications

Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy

Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis

Treatment of transthyretin cardiac amyloidosis

Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies